PCM
AGRX

Perkins Capital Management’s Agile Therapeutics AGRX Stock Holding History

Perkins Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$40K Buy
+11
New +$63.1K 0.05% 95

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perkins Capital Management's AGRX Position: Q1 2020 in Review

Perkins Capital Management opened a new position in Agile Therapeutics (AGRX) in Q1 2020: 11 shares worth $40K. The stake represents 0.05% of the portfolio and ranks #95 among its holdings.

61 funds tracked by Wall St. Rank hold AGRX as of Q1 2020.

  • Perkins Capital Management held 11 shares of Agile Therapeutics worth $40K as of Q1 2020.
  • Agile Therapeutics was a new Perkins Capital Management position in Q1 2020.
  • Agile Therapeutics made up 0.05% of Perkins Capital Management's portfolio in Q1 2020, its #95 holding.
  • 61 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2020.

Based on Perkins Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.